Raymond James Financial
CMPX icon

Raymond James Financial’s Compass Therapeutics CMPX Stock Holding History

Raymond James Financial’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Buy
121,889
+41,747
+52% +$241K ﹤0.01% 4178
2025
Q4 		$430K Buy
+80,142
New +$370K ﹤0.01% 4366
2025
Q3 		– Sell
-4,894
Closed -$12.7K – 5313
2025
Q2 		$12.7K Buy
+4,894
New +$10.1K ﹤0.01% 5815

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's CMPX Position: Q1 2026 in Review

Raymond James Financial increased its Compass Therapeutics (CMPX) stake by 52% in Q1 2026, buying an estimated $241K and bringing the position to 121,889 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #4178.

Raymond James Financial first reported a position in CMPX in Q2 2025 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Raymond James Financial held 121,889 shares of Compass Therapeutics worth $645K as of Q1 2026.
  • Raymond James Financial bought 41,747 Compass Therapeutics shares in Q1 2026, an estimated $241K.
  • Compass Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4178 holding.
  • Raymond James Financial first reported a position in Compass Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.